Improving quality of life in patients with metastatic prostate cancer following one cycle of 177Lu-PSMA-617 radioligand therapy: a pilot study
M Marinova, R Alamdar… - Nuklearmedizin …, 2020 - thieme-connect.com
… of PSMA targeted radioligand therapy with 177 Lu-PSMA-617 … -related quality of life (QoL)
in patients undergoing PSMA … median 73.5 years) undergoing 177 Lu-PSMA-617 therapy from …
in patients undergoing PSMA … median 73.5 years) undergoing 177 Lu-PSMA-617 therapy from …
Improved Quality of Life in Metastatic Castration-Resistant Prostate Cancer Patients Receiving Consecutive Cycles of 177Lu-PSMA I&T
A Karimzadeh, P Soeiro, B Feuerecker… - Journal of Nuclear …, 2023 - Soc Nuclear Med
… The results of our analysis indicate a beneficial impact of 177 Lu-PSMA RLT on QoL for
mCRPC patients. Patients showed improvement in HRQoL and alleviation in relevant disease-…
mCRPC patients. Patients showed improvement in HRQoL and alleviation in relevant disease-…
177Lu-PSMA radioligand therapy for prostate cancer
WP Fendler, K Rahbar, K Herrmann… - Journal of Nuclear …, 2017 - Soc Nuclear Med
… In summary, 177 Lu-PSMA RLT may be considered in … PSMA expression of tumor and
metastases, ideally by baseline … patients, an improved quality of life in 60%, and an improved …
metastases, ideally by baseline … patients, an improved quality of life in 60%, and an improved …
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
… We aimed to investigate the safety, efficacy, and effect on quality of life of [ 177 Lu]-PSMA-…
[ 177 Lu]-PSMA-617 has promising anti-tumour activity, low toxicity, and improves quality of life …
[ 177 Lu]-PSMA-617 has promising anti-tumour activity, low toxicity, and improves quality of life …
Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center phase II prospective trial of 177Lu-PSMA-617 theranostics in metastatic …
… Furthermore, we also observed improvement in quality-of-life measures. Radiation … who
subsequently received additional cycles of 177 Lu-PSMA therapy or other systemic therapies at …
subsequently received additional cycles of 177 Lu-PSMA therapy or other systemic therapies at …
Radioligand Therapy With 177Lu-PSMA for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
MP Yadav, S Ballal, RK Sahoo… - American Journal of …, 2019 - Am Roentgen Ray Soc
… safety, and quality of life associated with 177 Lu-PSMA RLT. The … provides evidence that 177
Lu-PSMA RLT has promising … revealed a higher rate of response to 177 Lu-PSMA RLT. Kim …
Lu-PSMA RLT has promising … revealed a higher rate of response to 177 Lu-PSMA RLT. Kim …
576MO Health-related quality of life (HRQoL), pain and safety outcomes in the phase III VISION study of 177Lu-PSMA-617 in patients with metastatic castration …
K Fizazi, K Herrmann, BJ Krause, K Rahbar… - Annals of …, 2021 - annalsofoncology.org
… patients ( 177 Lu-PSMA-617 arm, n = 385; control arm, n = 196). HRQoL and pain time-to-worsening
analyses favoured the 177 Lu-PSMA-617 arm (Table), despite a higher incidence …
analyses favoured the 177 Lu-PSMA-617 arm (Table), despite a higher incidence …
177Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
… treatments, such as 177 Lu-PSMA-617/I&T therapy … 177 Lu-PSMA-617/I&T therapy was
reported to lead to pain relief in 33–70% of patients, improved quality of life in 60% and improved …
reported to lead to pain relief in 33–70% of patients, improved quality of life in 60% and improved …
177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment
MP Yadav, S Ballal, M Tripathi, NA Damle… - European journal of …, 2017 - Springer
… Because of the extensive spread and proliferation of disease a shorter time gap between
the therapy cycles and higher dosage of 177 Lu-DKFZ-PSMA-617 therapy may be adopted as …
the therapy cycles and higher dosage of 177 Lu-DKFZ-PSMA-617 therapy may be adopted as …
Improving Overall Survival and Quality of Life in Patients with Prostate Cancer and Neuroendocrine Tumors Using 177Lu-iPSMA and 177Lu-DOTATOC: Experience …
M Luna-Gutiérrez, R Hernández-Ramírez… - Pharmaceutics, 2023 - mdpi.com
… dosimetry in patients of a novel 177 Lu-labeled PSMA inhibitor ( 177 Lu-iPSMA) (Mexico-ININ)
for prostate cancer therapy [9,10,11], as well as the pharmaceutical grade preparation of …
for prostate cancer therapy [9,10,11], as well as the pharmaceutical grade preparation of …
相关搜索
- 177lu psma improving quality of life
- 177lu psma prostate cancer
- 177lu psma androgen receptor pathway inhibitor
- 177lu psma single center study
- 177lu psma prognostic factors
- consecutive cycles 177lu psma i&t
- 177lu psma radioligand therapy
- 177lu psma meta analysis
- 177lu psma developing south asian country
- 177lu psma overall survival
- 177lu psma predictive factors
- 177lu psma randomized phase
- 177lu psma health related quality
- 177lu psma radionuclide treatment
- one cycle improving quality of life
- 177lu psma east asians